Evercore ISI analyst Joshua Schimmer raised the firm’s price target on TG Therapeutics (TGTX) to $25 from $16 and keeps an Outperform rating on the shares. The firm checked in with some high-prescribing neurologists following Briumvi’s approval for MS and came away with a greater appreciation of nuances that position Briumvi for "meaningful share gains" versus Roche’s Ocrevus, making it "significantly more bullish" about TG Therapeutics shares.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TGTX:
- TG Therapeutics call volume above normal and directionally bullish
- TG Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
- TG Therapeutics price target raised to $23 from $19 at Jefferies
- TG Therapeutics price target raised to $16 from $11 at Evercore ISI
- Another Big Day for TGTX
